Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelarabine in Relapsed/Refractory Non-T-cell ALL
NCT00006020Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Jul 2000
- Primary completion
- Jun 2004
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelarabine in acute lymphoblastic leukemia (ALL), sponsored by SWOG Cancer Research Network. Primary endpoint: Complete Remission Rate. Started Jul 2000; status: completed.
02
Drugs
nelarabine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00006020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006020.